Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2023-09-11 Sale | 2023-09-13 4:11 pm | Zentalis Pharmaceuticals Inc. | ZNTL | Skvarka Jan Director | 5,000 | $25.05 | $125,238 | 47,970 (Direct) | View |
2021-05-11 Sale | 2021-05-13 4:12 pm | Trillium Therapeutics Inc. | TRIL | Skvarka Jan President and CEO | 130,500 | $9.2083 | $1,201,683 | 1,580,302 (Direct) | View |
2021-01-13 Sale | 2021-01-15 4:19 pm | Trillium Therapeutics Inc. | TRIL | Skvarka Jan President and CEO | 25,000 | $15.03 | $375,787 | 2,519,581 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-06-21 Option Award | 2024-06-21 5:11 pm | N/A N/A | Zentalis Pharmaceuticals Inc. | ZNTL | Skvarka Jan Director | 41,581 | $0 | 89,551 (Direct) | View |
2024-06-12 Option Award | 2024-06-13 4:30 pm | N/A 2034-06-12 | Monte Rosa Therapeutics Inc. | GLUE | Skvarka Jan Director | 22,100 | $0 | 22,100 (Direct) | View |
2023-06-16 Option Award | 2023-06-16 5:01 pm | N/A N/A | Zentalis Pharmaceuticals Inc. | ZNTL | Skvarka Jan Director | 16,364 | $0 | 52,970 (Direct) | View |
2023-06-14 Option Award | 2023-06-15 4:29 pm | N/A 2033-06-13 | Monte Rosa Therapeutics Inc. | GLUE | Skvarka Jan Director | 20,500 | $0 | 20,500 (Direct) | View |
2023-03-30 Option Award | 2023-03-31 4:15 pm | N/A 2033-03-29 | Monte Rosa Therapeutics Inc. | GLUE | Skvarka Jan Director | 41,000 | $0 | 41,000 (Direct) | View |
2022-09-09 Option Award | 2022-09-12 07:07 am | N/A N/A | Zentalis Pharmaceuticals Inc. | ZNTL | Skvarka Jan Director | 36,606 | $0 | 36,606 (Direct) | View |
2021-11-17 Disposition | 2021-11-19 1:20 pm | N/A 2029-11-07 | Trillium Therapeutics Inc. | TRIL | Skvarka Jan President and CEO | 1,959,500 | $0 | 0 (Direct) | View |
2021-05-11 Exercise | 2021-05-13 4:12 pm | N/A N/A | Trillium Therapeutics Inc. | TRIL | Skvarka Jan President and CEO | 43,000 | $0.314 | 1,580,302 (Direct) | View |
2021-05-11 Exercise | 2021-05-13 4:12 pm | N/A N/A | Trillium Therapeutics Inc. | TRIL | Skvarka Jan President and CEO | 87,500 | $0.4462 | 1,580,302 (Direct) | View |
2021-05-11 Exercise | 2021-05-13 4:12 pm | N/A 2029-09-25 | Trillium Therapeutics Inc. | TRIL | Skvarka Jan President and CEO | 130,500 | $0 | 1,580,302 (Direct) | View |
2021-01-13 Exercise | 2021-01-15 4:19 pm | N/A N/A | Trillium Therapeutics Inc. | TRIL | Skvarka Jan President and CEO | 5,419 | $0.4248 | 2,519,581 (Direct) | View |
2021-01-14 Exercise | 2021-01-15 4:19 pm | N/A N/A | Trillium Therapeutics Inc. | TRIL | Skvarka Jan President and CEO | 19,581 | $0.4275 | 2,519,581 (Direct) | View |
2021-01-13 Exercise | 2021-01-15 4:19 pm | N/A 2029-09-25 | Trillium Therapeutics Inc. | TRIL | Skvarka Jan President and CEO | 25,000 | $0 | 2,519,581 (Direct) | View |
Ownership | 2021-01-04 8:11 pm | N/A 2030-12-23 | Trillium Therapeutics Inc. | TRIL | Skvarka Jan President and CEO | 0 | $0 | 2,115,000 (Direct) | View |